Table 1. Viability (%) of chronic lymphocytic leukemia (CLL) cells after a 6-h treatment with MGCD0103 and flavopiridol alone or in combination.

	MGCD0103 (μM)
	0	0.05	0.1	0.2	0.4	0.8
Flavopiridol (μM)
0	100	104.12±6.51	96.91±8.16	101.15±10.50	97.33±9.30	86.74±14.42
0.1875	92.90±14.70	78.16±19.59
0.375	96.22±14.51		80.59±20.37
0.75	89.32±16.90			79.88±23.77
1.5	92.89±11.64				70.68±14.71
3	83.42±9.21					68.70±16.50

Peripheral blood mononuclear cells (PBMCs) from CLL patients (n=5) were incubated with various concentrations of MGCD0103 and flavopiridol, either alone or simultaneously, for 6 h. Combination experiments were done using a constant ratio design. Viability was determined by a CCK-8 colorimetric assay. Each sample was run in triplicate and was normalized to cells incubated without drug. Data represent the mean values±s.d.